Superagers aged 80 years and older demonstrate a unique neurobiological profile associated with successful aging: preserved memory and distinct brain anatomy, including thicker cortical regions and lower tau pathology.
Subgroup analyses demonstrated a greater reduction in neurologic events than psychiatric events, though the reduction in psychiatric events was not statistically significant.
"The panel urges clinicians to consider the pretest probability of AD pathology for each patient when deciding whether or not to use a BBM test,” and not as a standalone diagnostic tool.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.
Not all screen time is created equal. That’s the message from a recent editorial, which challenges the idea that all forms of problematic internet use led to the same cognitive consequences.